SLC7A11表达与双硫死亡、铁死亡及肿瘤关系的研究进展

摘要
图/表
参考文献(0)
相关文章 (15)

全文: PDF (3734 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要研究已发现数十种调节性细胞死亡方式，包括铜死亡、铁死亡以及新鉴定的双硫死亡(disulfidptosis)等。其中，双硫死亡是由细胞内过量胱氨酸积累引起的二硫化物应激导致的细胞死亡方式，通常在葡萄糖饥饿的条件下发生。溶质载体家族7成员11(solute carrier family 7 member 11，SLC7A11)作为参与多种新型细胞死亡方式的特定分子在肿瘤生长或进程中发挥了关键作用。本文针对双硫死亡并围绕其关键分子SLC7A11在肿瘤中的研究进展作一综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	赵琪琪1
	2
	杜雪芹2
	刘松华2
	刘斌2
	王彦泽3
	杨晓军2
	4
	5
	6

关键词 ：溶质载体家族7成员11(SLC7A11), 双硫死亡, 铁死亡, 肿瘤

收稿日期: 2023-03-28

基金资助:国家自然科学基金资助项目(81660398)；甘肃省创新基地和人才项目(20JR10RA433)；甘肃省省级科技计划重点研发项目(21YF5WA027)；甘肃省卫生健康行业科研计划(GSWSKY2020-45)；甘肃省人民医院院内科研基金资助项目(22GSSYD-60)

通讯作者: 杨晓军(通讯作者)，主任医师，博士生导师，E-mail： yangxjmd@aliyun.com

作者简介: 赵琪琪(1992—)，女，硕士研究生；

引用本文:

赵琪琪1，2，杜雪芹2，刘松华2，刘斌2，王彦泽3，杨晓军2,4,5,6. SLC7A11表达与双硫死亡、铁死亡及肿瘤关系的研究进展[J]. 江苏大学学报:医学版, 2023, 33(05): 398-403.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2023/V33/I05/398

［1］Bannai S, Kitamura E. Adaptive enhancement of cystine and glutamate uptake in human diploid fibroblasts in culture［J］. Biochim Biophys Acta, 1982, 721(1): 1-10.
［2］Sharma MK, Seidlitz EP, Singh G. Cancer cells release glutamate via the cystine/glutamate antiporter［J］. Biochem Biophys Res Commun, 2010, 391(1): 91-95.
［3］Koppula P, Zhang Y, Shi J, et al. The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate［J］. J Biol Chem, 2017, 292(34): 14240-14249.
［4］Liu X, Nie L, Zhang Y, et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis［J］. Nat Cell Biol, 2023, 25(3): 404-414.
［5］Liu X, Olszewski K, Zhang Y, et al. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer［J］. Nat Cell Biol, 2020, 22(4): 476-486.
［6］Stockwell BR. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications［J］. Cell, 2022, 185(14): 2401-2421.
［7］Ji X, Qian J, Rahman SMJ, et al. xCT (SLC7A11)mediated metabolic reprogramming promotes nonsmall cell lung cancer progression［J］. Oncogene, 2018, 37(36): 5007-5019.
［8］Bridges RJ, Natale NR, Patel SA. System xc- cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS［J］. Br J Pharmacol, 2012, 165(1): 20-34.
［9］Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy［J］. Protein Cell, 2021, 12(8): 599-620.
［10］Lee J, Roh JL. SLC7A11 as a gateway of metabolic perturbation and ferroptosis vulnerability in cancer［J］. Antioxidants (Basel), 2022, 11(12): 2444.
［11］Gao J, Li Y, Song R. SIRT2 inhibition exacerbates p53mediated ferroptosis in mice following experimental traumatic brain injury［J］. Neuroreport, 2021, 32(12): 1001-1008.
［12］Luo Y, Gao X, Zou L, et al. Bavachin induces ferroptosis through the STAT3/P53/SLC7A11 axis in osteosarcoma cells［J］. Oxid Med Cell Longev, 2021, 2021: 1783485.
［13］Guan Z, Chen J, Li X, et al. Tanshinone ⅡA induces ferroptosis in gastric cancer cells through p53mediated SLC7A11 downregulation［J］. Biosci Rep, 2020, 40(8): BSR20201807.
［14］Chen L, Qiao L, Bian Y, et al. GDF15 knockdown promotes erastininduced ferroptosis by decreasing SLC7A11 expression［J］. Biochem Biophys Res Commun, 2020, 526(2): 293-299.
［15］Robert SM, Buckingham SC, Campbell SL, et al. SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma［J］. Sci Transl Med, 2015, 7(289): 289ra86.
［16］Liu XX, Li XJ, Zhang B, et al. MicroRNA26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11［J］. FEBS Lett, 2011, 585(9): 1363-1367.
［17］Guo W, Zhao Y, Zhang Z, et al. Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma［J］. Cancer Lett, 2011, 312(1): 55-61.
［18］Li S, Lu Z, Sun R, et al. The role of SLC7A11 in cancer: friend or foe?［J］. Cancers (Basel), 2022, 14(13): 3059.
［19］赵亦非, 王宝华. miR375靶向SLC7A11调控口腔鳞癌细胞增殖、侵袭的研究分析［J］. 解放军预防医学杂志, 2019, 37(5): 145-147.
［20］Patel D, Kharkar PS, Gandhi NS, et al. Novel analogs of sulfasalazine as system x-c antiporter inhibitors: Insights from the molecular modeling studies［J］. Drug Dev Res, 2019, 80(6): 758-777.
［21］Srensen MF, Heimisdóttir SB, Srensen MD, et al. High expression of cystineglutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma［J］. J Neurooncol, 2018, 138(1): 49-53.
［22］Roh JL, Kim EH, Jang H, et al. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition［J］. Free Radic Biol Med, 2017, 104: 1-9.
［23］Yamaguchi I, Yoshimura SH, Katoh H. High cell density increases glioblastoma cell viability under glucose deprivation via degradation of the cystine/glutamate transporter xCT (SLC7A11)［J］. J Biol Chem, 2020, 295(20): 6936-6945.
［24］Teramoto K, Katoh H. The cystine/glutamate antiporter xCT is a key regulator of EphA2 S897 phosphorylation under glucoselimited conditions［J］. Cell Signal, 2019, 62: 109329.
［25］Gu Y, Albuquerque CP, Braas D, et al. mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the cystineglutamate antiporter xCT［J］. Mol Cell, 2017, 67(1): 128-138.e7.
［26］Jyotsana N, Ta KT, DelGiorno KE. The role of cystine/glutamate antiporter SLC7A11/xCT in the pathophysiology of cancer［J］. Front Oncol, 2022, 12: 858462.
［27］Ye LF, Chaudhary KR, Zandkarimi F, et al. Radiationinduced lipid peroxidation triggers ferroptosis and synergizes with ferroptosis inducers［J］. ACS Chem Biol, 2020, 15(2): 469-484.
［28］Liu X, Zhang Y, Zhuang L, et al. NADPH debt drives redox bankruptcy: SLC7A11/xCTmediated cystine uptake as a doubleedged sword in cellular redox regulation［J］. Genes Dis, 2021, 8(6): 731-745.
［29］Hu N, Hu WH, Zhou SL, et al. SLC7A11 negatively associates with mismatch repair gene expression and endows glioblastoma cells sensitive to radiation under low glucose conditions［J］. Neoplasma, 2021, 68(6): 1147-1156.
［30］Wei BY, Kong W, Mou XY, et al. Comprehensive analysis of tumor immune infiltration associated with endogenous competitive RNA networks in lung adenocarcinoma［J］. Pathol Res Pract， 2019, 215(1): 159-170.
［31］Ma L, Chen T, Zhang X, et al. The m6A reader YTHDC2 inhibits lung adenocarcinoma tumorigenesis by suppressing SLC7A11dependent antioxidant function［J］. Redox Biol, 2021, 38: 101801.
［32］Iida Y, OkamotoKatsuyama M, Maruoka S, et al. Effective ferroptotic smallcell lung cancer cell death from SLC7A11 inhibition by sulforaphane［J］. Oncol Lett, 2021, 21(1): 71.
［33］Chen RS, Song YM, Zhou ZY, et al. Disruption of xCT inhibits cancer cell metastasis via the caveolin1/βcatenin pathway［J］. Oncogene, 2009, 28(4): 599-609.
［34］Polewski MD, ReveronThornton RF, Cherryholmes GA, et al. SLC7A11 overexpression in glioblastoma is associated with increased cancer stem celllike properties［J］. Stem Cells Dev, 2017, 26(17): 1236-1246.
［35］Miyoshi S, Tsugawa H, Matsuzaki J, et al. Inhibiting xCT improves 5Fluorouracil resistance of gastric cancer induced by CD44 variant 9 expression［J］. Anticancer Res, 2018, 38(11): 6163-6170.
［36］Zhang L, Huang Y, Ling J, et al. Overexpression of SLC7A11: a novel oncogene and an indicator of unfavorable prognosis for liver carcinoma［J］. Future Oncol, 2018, 14(10): 927-936.
［37］Wada F, Koga H, Akiba J, et al. High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine［J］. Cancer Sci, 2018, 109(9): 2801-2810.
［38］张萌, 刘旭明, 麦皓尘, 等. SLC7A11在KRAS突变胰腺癌中的表达及临床意义［J］. 实用医学杂志, 2022, 38(24): 3125-3128, 3134.
［39］Chen X, Yu C, Kang R, et al. Cellular degradation systems in ferroptosis［J］. Cell Death Differ, 2021, 28(4): 1135-1148.
［40］Lin W, Wang C, Liu G, et al. SLC7A11/xCT in cancer: biological functions and therapeutic implications［J］. Am J Cancer Res, 2020, 10(10): 3106- 3126.
［41］Zhu JH, De Mello RA, Yan QL, et al. MiR1395p/SLC7A11 inhibits the proliferation, invasion and metastasis of pancreatic carcinoma via PI3K/Akt signaling pathway［J］. Biochim Biophys Acta Mol Basis Dis, 2020, 1866(6): 165747.
［42］Yang Q, Li K, Huang X, et al. lncRNA SLC7A11AS1 promotes chemoresistance by blocking SCFβTRCPmediated degradation of NRF2 in pancreatic cancer［J］. Mol Ther Nucleic Acids, 2020, 19: 974-985.
［43］Tang R, Hua J, Xu J, et al. The role of ferroptosis regulators in the prognosis, immune activity and gemcitabine resistance of pancreatic cancer［J］. Ann Transl Med, 2020, 8(21): 1347.
［44］王建国, 陶耀业, 陈成, 等. SLC7A11蛋白在肝内胆管细胞癌组织中的表达及临床意义［J］. 浙江临床医学, 2021, 23(10): 1394-1396.
［45］朱明镒. SLC7A11在结直肠癌中的表达及其与微卫星不稳定的相关性研究［D］. 承德: 承德医学院, 2022.
［46］Dai Z, Huang Y, Sadee W, et al. Chemoinformatics analysis identifies cytotoxic compounds susceptible to chemoresistance mediated by glutathione and cystine/glutamate transport system xc-［J］. J Med Chem, 2007, 50(8): 1896-1906.
［47］Xu X, Zhang X, Wei C, et al. Targeting SLC7A11 specifically suppresses the progression of colorectal cancer stem cells via inducing ferroptosis［J］. Eur J Pharm Sci, 2020, 152: 105450.
［48］Lee N, Carlisle AE, Peppers A, et al. xCTdriven expression of GPX4 determines sensitivity of breast cancer cells to ferroptosis inducers［J］. Antioxidants (Basel), 2021, 10(2): 317.
［49］Hong T, Lei G, Chen X, et al. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCAproficient ovarian cancer［J］. Redox Biol, 2021, 42: 101928.
［50］杜红飞, 庞雪利, 阳燕, 等. SLC7A11在膀胱癌组织及细胞中的表达及意义［J］. 现代肿瘤医学, 2021, 29(21): 3792-3797.
［51］Drayton RM, Dudziec E, Peter S, et al. Reduced expression of miRNA27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11［J］. Clin Cancer Res, 2014, 20(7): 1990-2000.
［52］任宗涛, 马永良, 卫书飞, 等. 铁死亡相关蛋白SLC7A11及GPX4在肾细胞癌中的表达及意义［J］. 现代肿瘤医学, 2023, 31(2): 323-326.